CytRx Corp. (CYTR) Initiates Phase 1b Clinical Program for Chemotherapeutic

QualityStocks would like to highlight CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: bafetinib, tamibarotene and INNO-206.

In the company’s news yesterday,

CyRx Corp announced that it has commenced an open-label phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, Calif., with up to 24 patients with advanced solid tumors who have failed standard therapies.

INNO-206 is a tumor-targeting pro-drug of doxorubicin, the only FDA-approved, and commonly prescribed chemotherapeutic used as a standard treatment for a variety of cancers. INNO-206 is designed to improve efficacy and reduce adverse events through controlled release and preferential targeting of tumors.

“Determining the maximum dose of INNO-206 in patients with solid tumors is a major step forward in advancing this oncology drug candidate’s development,” CytRx president and CEO Steven A. Kriegsman stated in the press release. “We have already completed drug formulation and manufacturing optimization in anticipation of moving rapidly into phase 2 clinical programs following completion of this clinical trial.

The company noted that objective clinical responses have been seen with INNO-206 in patients with sarcoma, breast and lung cancers in an earlier phase 1 trial. Kriegsman said the phase 1b trial will provide the company with significant information, as it is the first of several indications for planned phase 2 clinical testing.

“This clinical trial will allow us to evaluate the safety of administering doses of INNO-206 that are over 2 to 4 times the standard dose of doxorubicin, which we believe we can accomplish without an increase in observed side effects over those historically seen with doxorubicin. We are encouraged by the fact that INNO-206 has demonstrated significantly greater efficacy than doxorubicin in animal models of breast cancer, small cell lung cancer, renal cancer, pancreatic cancer and ovarian cancer,” Daniel Levitt, MD, Ph.D., chief medical officer for CyRx stated.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.